Global Biocatalysts Industry Research 2024-2035: In-Depth
Dublin, May 22, 2024 (GLOBE NEWSWIRE) -- The
Source: globenewswire.com
📰 Rational Design News
Rational Design News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Rational Design. Real-time updates on events, politics, business and more.
ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma ("R/R B-NHL") -April 09, 2024 at 05:30 pm EDT
– Twenty patients with indolent and aggressive R/R B-NHL received evorpacept plus standard rituximab and lenalidomide – Evorpacept plus R2 was well tolerated with a safety profile similar to...
United States Sophia Randolph Caitlyn Doherty Development Pillars American Cancer Society American Association For Cancer Research
Source: marketscreener.com
ALX Oncology Reports Encouraging Clinical Data of
– Twenty patients with indolent (n=18) and aggressive (n=2) R/R B-NHL received evorpacept plus standard rituximab and lenalidomide (“R2”)– Evorpacept plus...
United States Sophia Randolph Caitlyn Doherty Exchange Commission University Of Texas Md Anderson Cancer Center American Cancer Society
Source: globenewswire.com
ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with ...
– Twenty patients with indolent (n=18) and aggressive (n=2) R/R B-NHL received evorpacept plus standard rituximab and lenalidomide (“R2”)
United States Caitlyn Doherty Sophia Randolph Oncology Holdings Inc Corporate Communications University Of Texas Md Anderson Cancer Center
Source: eagletribune.com
How smart nanofiber meshes can be used as a local drug delivery platform
This article from Merck outlines how nanofiber meshes are used as local drug delivery platforms.
Source: news-medical.net
ALX Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway,
Source: eagletribune.com
ALX Oncology Announces September Investor Conference Participation
SOUTH SAN FRANCISCO, Calif., Aug. 31, 2023 -- ALX Oncology Holdings Inc., , a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced...
Source: marketscreener.com
ALX Oncology Announces September Investor Conference Participation - ALX Oncology Holdings (NASDAQ:ALXO)
SOUTH SAN FRANCISCO, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology") (NASDAQ:ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint
Source: benzinga.com
Monte Rosa Therapeutics to Present at Upcoming Investor and
BOSTON, May 30, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular...
United States New York Monte Rosa Therapeutics Inc International Healthcare Conference Rosa Therapeutics Healthcare Conference
Source: globenewswire.com
Enhancing Next-Gen Electrolytes for Low Temperatures
Researchers created a new and safer electrolyte for lithium-ion batteries that performs just as well in subzero temperatures as it does at room temperature.
Source: azocleantech.com